LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Accueil・Liste d'Actions・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Fermé

SecteurSoins de santé

696.2 -2.26

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

691.67

Max

714.95

Chiffres clés
By Trading Economics
Revenu	-117M 727M
Ventes	-279M 3.6B
P/E Moyenne du Secteur	17.393 51.415
BPA	9.47
Rendement du dividende	0.5
Marge bénéficiaire	20.17
Employés	15,343
EBITDA	-234M 967M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+24.13% upside

Dividendes
By Dow Jones
Rendement du dividende Moyenne du Secteur	0.50% 2.34%
Prochains Résultats	31 juil. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-3.3B 75B
Ouverture précédente	698.46
Clôture précédente	696.2

Sentiment de l'Actualité

By Acuity

39%

61%

122 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

542.44 / 599.76 Support & Résistance

Regeneron Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 août 2025, 11:33 UTC

Résultats

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

29 avr. 2026, 12:01 UTC

Résultats

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

23 avr. 2026, 21:48 UTC

Acquisitions, Fusions, Rachats

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

11 mars 2026, 11:02 UTC

Market Talk

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

14 déc. 2025, 08:30 UTC

Acquisitions, Fusions, Rachats

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

1 août 2025, 13:16 UTC

Résultats

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 août 2025, 12:40 UTC

Résultats

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 août 2025, 10:41 UTC

Résultats

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

1 août 2025, 10:41 UTC

Résultats

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

1 août 2025, 10:40 UTC

Résultats

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

1 août 2025, 10:38 UTC

Résultats

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

1 août 2025, 10:37 UTC

Résultats

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

1 août 2025, 10:35 UTC

Résultats

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

1 août 2025, 10:34 UTC

Résultats

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

1 août 2025, 10:33 UTC

Résultats

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

1 août 2025, 10:32 UTC

Résultats

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

1 août 2025, 10:31 UTC

Résultats

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

1 août 2025, 10:31 UTC

Résultats

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

1 août 2025, 10:30 UTC

Résultats

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

1 août 2025, 10:30 UTC

Résultats

Regeneron Pharma 2Q Rev $3.68B >REGN

1 août 2025, 10:30 UTC

Résultats

Regeneron Pharma 2Q EPS $12.81 >REGN

1 août 2025, 10:30 UTC

Résultats

Regeneron Pharma 2Q Net $1.39B >REGN

13 juin 2025, 21:42 UTC

Acquisitions, Fusions, Rachats

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 juin 2025, 20:45 UTC

Acquisitions, Fusions, Rachats

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 juin 2025, 20:34 UTC

Acquisitions, Fusions, Rachats

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 juin 2025, 20:14 UTC

Acquisitions, Fusions, Rachats

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 juin 2025, 20:14 UTC

Acquisitions, Fusions, Rachats

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 juin 2025, 20:14 UTC

Acquisitions, Fusions, Rachats

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

5 juin 2025, 01:41 UTC

Acquisitions, Fusions, Rachats

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

30 mai 2025, 08:58 UTC

Actions en Tendance

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

Comparaison

Variation de prix

Regeneron Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

24.13% hausse

Prévisions sur 12 Mois

Moyen 884.89 USD 24.13%

Haut 1,057 USD

Bas 762 USD

Basé sur 19 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

19 ratings

Achat

Maintien

Vente

Basé sur 19 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

542.44 / 599.76Support & Résistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

122 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.